FAT LOSS · RECOVERY
Peptides for Obesity
GLP-1 and dual-incretin compounds have changed obesity treatment more in the last 5 years than the previous 40. Two compounds — incretin-class and joint recovery — match the medical and mobility load.
Audience protocol path
How to move from obese adults research to a safer plan.
- 1
Baseline
Clarify goal, labs, contraindications, and sport/testing status.
- 2
Choose
Pick one primary compound path before stacking extras.
- 3
Source
Check vendor documentation, COA fit, and route constraints.
- 4
Monitor
Track outcomes, adverse effects, and stop conditions.
- 5
Reassess
Review whether the protocol still fits after the first cycle.
§ Safety surface
Coordinate with a clinician
GLP-1s require dose titration, monitoring, and discontinuation planning — not a self-managed protocol.
Protein and resistance training are not optional
Lean mass loss on GLP-1s can be substantial without high protein intake and resistance training.
Quick answer
Clinical obesity (BMI 30+) is now treatable with GLP-1 and dual-incretin compounds that produce 15–22% sustained weight loss in clinical trials. BPC-157 addresses the joint and soft-tissue load that obesity places on the body during the loss phase.
Audience-specific next step
Match this obese adults research to your profile.
Take the quiz before choosing a compound, vendor, or PDF so recommendations reflect your goals, life stage, and risk constraints.
Why obese adults need a different approach
Obesity is no longer a willpower problem to be lectured at. Modern treatment is pharmaceutical — and effective.
- 01
STEP and SURMOUNT trials demonstrated 15–22% sustained weight loss with semaglutide and tirzepatide respectively — comparable to bariatric surgery for many patients.
- 02
Weight regain after discontinuation is substantial; most patients require continued therapy to maintain losses.
- 03
Lean mass loss can reach 30–40% of total weight lost without resistance training and high protein intake.
The 2-compound starter set for obese adults
One compound per priority goal — derived from the goal × age × sex data layer, not from a top-ten list. Tier reflects evidence strength.
- 01 / 02TIER A
For fat loss & metabolism
Semaglutide
aka Ozempic· medium riskGLP-1 and dual-incretin compounds produce 15–22% sustained weight loss in clinical trials — the largest shift in obesity treatment in decades.
Evidence
Tier A
Risk
medium
Route
subcutaneous
- Study dose
- Approved human use: 0.25 mg to 2.4 mg weekly subcutaneous; oral semaglutide 3 mg to 14 mg daily.
- Onset
- Glucose effects emerge over the first weeks; weight-loss effects build across 3 to 12 months.
- Category
- metabolic
- 02 / 02TIER C
For tissue repair & recovery
BPC-157
aka Body Protection Compound 157· med high riskCarrying excess weight loads joints continuously; BPC-157 addresses the soft-tissue maintenance burden during and after weight loss.
Evidence
Tier C
Risk
med high
Route
subcutaneous
- Study dose
- Rodent: ~10 µg/kg systemic; oral exposure at µg/kg levels. No established human dosing.
- Onset
- Animal models: endpoints assessed over days to weeks (2-4 weeks in injury models).
- Category
- tissue repair
Protein, lifting, and weight loss in parallel
The single biggest mistake on GLP-1s is losing muscle alongside fat. Aim for 1 gram of protein per pound of target body weight, resistance train at least 3× per week, and track lean mass with a DEXA or BIA scan every 8–12 weeks. The goal is fat loss, not weight loss in the abstract.
Indications and clinical thresholds
Obesity treatment is now a pharmaceutical discipline with clear guideline-directed thresholds. The case for a GLP-1 is no longer cosmetic — it is clinical, with cardiovascular and metabolic outcomes data. The decision is when and which compound, not whether to use peptides.
- 01
BMI ≥ 30, or BMI ≥ 27 with a weight-related comorbidity — guideline threshold for pharmacotherapy.
- 02
Tirzepatide vs semaglutide: comparable safety, larger weight-loss effect for tirzepatide; price and access often dictate choice.
- 03
BPC-157 as adjunct for joint loading complaints during rapid weight loss — short courses, training-coordinated.
- 04
Bariatric surgery candidacy — coordinate with surgical team; peptide use after surgery has specific protocols.
Discipline for a multi-year arc
Modern obesity treatment is a multi-year arc, not a cycle. Weight regain after discontinuation is the rule in clinical trials. Plan dosing, monitoring, and transition off as a single long protocol — and protect lean mass aggressively throughout, because the lean mass you lose at 40 does not fully return.
- 01
Titrate slowly per label — the most common failure is escalating too fast and dropping out from GI side effects.
- 02
Repeat full panel every 3 months — fasting glucose, HbA1c, lipid panel with ApoB, kidney function, liver enzymes.
- 03
DEXA or BIA at baseline and every 8–12 weeks — track lean mass loss as carefully as fat loss.
- 04
Coordinate with primary care; flag interactions with BP medications, statins, and any psychiatric medications.
What changes when you reach a stable weight
Reaching target weight is the start of the maintenance arc, not the end of treatment. Maintenance protocols are individual — some patients transition to lower-dose maintenance, others stay at therapeutic dose indefinitely. The same monitoring cadence applies; the same lifestyle inputs remain non-negotiable.
- 01
Maintenance dosing decisions belong to your prescriber — discontinuation typically leads to regain.
- 02
Resistance training and high protein intake stay non-negotiable through maintenance.
- 03
Body composition monitoring continues every 3–6 months.
- 04
Read on for the related insulin-resistance trajectory:
Frequently asked questions
Q01How long do I need to stay on a GLP-1?
For most patients, indefinitely. Weight regain after discontinuation is the norm in clinical trials. Some patients can transition to lower-dose maintenance once at target weight, but this requires careful clinician guidance.
Q02Will I lose muscle on a GLP-1?
Yes, some. Lean mass loss accounts for 25–40% of total weight lost depending on protein intake and resistance training. Active patients with high protein intake preserve significantly more muscle than sedentary ones.
Q03Is tirzepatide better than semaglutide?
In head-to-head trials (SURMOUNT-5, 2024), tirzepatide produced greater weight loss than semaglutide at comparable durations. Side effect profiles are similar. Insurance coverage and cost often drive the practical choice.
§ Custom protocol
Get a protocol built for you, not for everyone.
Six questions match compounds, dosing, stacking, and timing to your goals, age, sex, and risk tolerance. Built in two minutes. Free.
Section hub
More from this section
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.